Business Wire

The Open Group OSDU™ Forum Launches the OSDU Data Platform Mercury Release

24.3.2021 12:00:00 EET | Business Wire | Press release

Share

The Open Group, the vendor-neutral technology consortium, today announced the OSDU Data Platform Mercury Release. Developed by The Open Group OSDU™ Forum, the OSDU Data Platform is an Open Source, standards-based and technology-agnostic data platform for the energy industry that stimulates innovation, industrializes data management, and reduces time to market for new solutions.

The OSDU Data Platform will provide over time access to a vast portfolio of open and proven vendor-developed applications from a broad range of energy sources. By accessing this ecosystem, developers no longer have to develop and maintain the monolithic architecture needed to deliver unique value-add services. Now, with a single set of well-defined and industry-specific APIs, organizations can easily accelerate platform design and develop proprietary applications on top of the OSDU Data Platform.

With an Open Source approach, any company – from established corporations to start-up challenger companies – can contribute new features to the platform, supporting a variety of business workflows. All work is validated by the OSDU Program Management Committee (PMC) to ensure it is aligned with the overall direction of the Forum.

With a single view of industry data, the OSDU Data Platform can be harnessed for innovative business applications. The Mercury Release of the OSDU Data Platform is now available to Operators and Software Developers who want to:

  • Liberate data from traditional silos and make all data discoverable and usable in a single data platform
  • Enable new integrated exploration and development workflows that reduce overall cycle time
  • Take advantage of emerging digital solutions to provide scalability and accelerate decision making

Steve Nunn, President and CEO of The Open Group, commented: “The OSDU Data Platform Mercury Release represents an important achievement by the OSDU Forum in a very short space of time. Established in 2018, the OSDU Forum has accumulated over 185 Member organizations who are collaborating together to accelerate innovation and reduce costs in the energy sector. With a standard data platform, energy companies will be able to drive innovation by integrating digital technologies and utilizing open standards for better decision making. Looking ahead, this will be imperative to meet the world’s increasing energy demands while reducing greenhouse gas emissions.”

Johan Krebbers, GM Emerging Digital Technologies / VP IT Innovation, Shell, commented: “At the heart of most energy companies’ strategies is embracing the transformational technologies taking us forward in today’s digital era. This makes the need for a common architectural design clear, one that underpins how our industry works with its data.”

David Eyton, EVP Innovation & Engineering, bp, commented: “Data is at the heart of bp’s transformation into an integrated energy company. We believe that the future of the energy industry will be data driven and dependent on its ability to manage data in a manner that promotes data sharing with partners, innovation through data science, and rapid decision making throughout the lifecycle of the energy value chains. Being a founding member of the OSDU Forum, bp has had an opportunity to be part of an organization that is fundamentally changing the data landscape for our industry. By integrating energy organizations, cloud services providers, and software vendors, the OSDU Forum is providing an opportunity for collaboration that will be beneficial for all involved. We are very excited about the Mercury Release of the OSDU Data Platform and look forward to expanding this approach into engineering, emissions, and new energy.”

To learn more about how to develop applications the OSDU Data Platform, visit the application developer community page here.

The current OSDU Forum Member List is available here.

-ENDS-

About The Open Group OSDU Forum

The Open Group OSDUTM Forum enables the Energy industry to develop transformational technology to support the world’s changing Energy needs. The OSDU Forum is available to all energy stakeholders including application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found here.

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. For more information, visit www.opengroup.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Jenny Morris
Hotwire
+44 (0)7393465529
UKOpengroup@hotwirepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye